Diagnostic Algorithm for Hepatocellular Carcinomas with TERT, TP53, and CTNNB1 Mutations

This study focuses on understanding the relationship between certain biomarkers and genetic mutations in liver cancer, specifically hepatocellular carcinoma (HCC). Researchers are examining if there is a link between the biomarkers p53 and beta-Catenin and genetic mutations TERT, TP53, and CTNNB1 in patients who have had part of their liver removed due to cancer. The study also looks at other biomarkers like Glutamin Synthetase, Glypican-3, and HSP70 to see how they relate to these genetic mutations. This research is important because finding these associations could improve how liver cancer is diagnosed and classified, potentially leading to better treatment options for patients. Participants in this study include about 100 patients who have already undergone liver surgery for HCC and have had their genetic profiles analyzed. The researchers will use samples previously collected and preserved to perform new tests, specifically immunohistochemistry, to further investigate the presence of these biomarkers. This approach allows the study to leverage existing patient data to explore the genetic and biomarker connections without needing new surgeries or procedures. This study carries minimal risk as it uses previously collected samples, and it aims to provide valuable insights into liver cancer diagnosis.